Literature DB >> 32507583

Malnutrition at diagnosis in amyotrophic lateral sclerosis (als) and its influence on survival: Using glim criteria.

Juan José López-Gómez1, María D Ballesteros-Pomar2, Beatriz Torres-Torres3, Begoña Pintor De la Maza4, M Ángeles Penacho-Lázaro5, José M Palacio-Mures6, Cristina Abreu-Padín7, Antonio López-Guzmán8, Daniel A De Luis-Román3.   

Abstract

BACKGROUND: Malnutrition is a prognostic factor in Amyotrophic Lateral Sclerosis (ALS). Sometimes, this condition is underdiagnosed, and it might influence on disease progression. AIMS: To evaluate a) nutritional status at the beginning of specialized nutritional treatment and b) the influence of initial nutritional status on disease evolution and survival in a group of patients with amyotrophic lateral sclerosis (ALS).
METHODS: An interhospital registry of patients with motor neuron disease treated at the Clinical Nutrition Clinics of six hospitals in the region of Castilla y León in Spain was created. The study was developed from January 2015 to December 2017. An anamnesis, affiliation data, past medical history, disease evolution, nutritional history and an anthropometry and bioelectrical impedance analysis were performed at baseline. The mortality rate was compared among those patients with worse nutritional status at the beginning of the follow-up against those with a better nutritional situation using two tools: The Subjective Global Assessment (SGA) and the criteria of the Global Leadership Initiative for Malnutrition (GLIM).
RESULTS: A total of 93 patients were analysed. The median age of the patients was 67 (57.5-75.5) years. The median Body Mass Index was 24.4 (21.7-25.9) kg/m2 and the median percentage of weight loss was 9.32 (2.7-17.6)% without differences between the onset type. According to the SGA, 27 (29%) patients were in grade A; 43 (46.3%) patients were in grade B and 23 (24.7%) were in grade C. According to the new GLIM malnutrition criteria, 45 patients (48.4%) had malnutrition. Patients with worse nutritional status had a lower survival median with both SGA (SGA A: 20.5 (10.2-35) months vs SGA B-C: 12 (5.2-23.7) months (p = 0.03)) or the new GLIM criteria according to severity (severe malnutrition: 18 (5-24) months vs. no severe malnutrition: 20 (12-33) months (p = 0.01)). In the multivariate analysis, malnutrition measured by SGA was an independent risk factor (HR: 4.6 (1.5-13.9) p = 0.007) for survival over 15 months when adjusted for age, sex and type of onset of ALS.
CONCLUSIONS: Patients with ALS have a severe deterioration in nutritional status when analysed using a classical malnutrition test (SGA) or a new one (GLIM criteria). Patients with a better nutritional situation according to SGA and GLIM severity classification were associated with a longer survival time.
Copyright © 2020 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Amyotrophic lateral sclerosis; Bioelectrical impedance analysis; Malnutrition diagnosis; Survival

Year:  2020        PMID: 32507583     DOI: 10.1016/j.clnu.2020.05.014

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  3 in total

Review 1.  Lipid Metabolic Alterations in the ALS-FTD Spectrum of Disorders.

Authors:  Juan Miguel Godoy-Corchuelo; Luis C Fernández-Beltrán; Zeinab Ali; María J Gil-Moreno; Juan I López-Carbonero; Antonio Guerrero-Sola; Angélica Larrad-Sainz; Jorge Matias-Guiu; Jordi A Matias-Guiu; Thomas J Cunningham; Silvia Corrochano
Journal:  Biomedicines       Date:  2022-05-10

2.  The potential benefit of leptin therapy against amyotrophic lateral sclerosis (ALS).

Authors:  Agueda Ferrer-Donato; Ana Contreras; Paloma Fernandez; Carmen M Fernandez-Martos
Journal:  Brain Behav       Date:  2021-12-21       Impact factor: 2.708

3.  Correlation of weight and body composition with disease progression rate in patients with amyotrophic lateral sclerosis.

Authors:  Jin-Yue Li; Xiao-Han Sun; Zheng-Yi Cai; Dong-Chao Shen; Xun-Zhe Yang; Ming-Sheng Liu; Li-Ying Cui
Journal:  Sci Rep       Date:  2022-08-02       Impact factor: 4.996

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.